{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T11:39:09Z","timestamp":1782301149966,"version":"3.54.5"},"reference-count":53,"publisher":"The Endocrine Society","issue":"3","license":[{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Whether continuation of dipeptidyl peptidase-4 inhibitors (DPP-4is) or switching to oral semaglutide is more beneficial for \u03b2-cell function is unclear.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To assess the efficacy of switching from DPP-4is to oral semaglutide for \u03b2-cell function compared with DPP-4i continuation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Post hoc analysis of SWITCH-SEMA 2, a multicenter prospective randomized controlled trial on the switch to oral semaglutide vs DPP-4i continuation without dose adjustment for 24 weeks in subjects with type 2 diabetes treated with DPP-4is, was conducted. Changes in markers for glucose metabolism, including homeostatic model assessment (HOMA2) scores and disposition index (DI), were compared between the groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 146 subjects (semaglutide group, 69; DPP-4i group, 77) were analyzed. In the semaglutide group, glycemic control, liver enzyme deviations, and lipid profiles improved after 24 weeks. Regarding indices for \u03b2-cell function, changes in HOMA2-\u03b2 as well as DI, reflecting the ability of \u03b2-cells to compensate for insulin resistance, were significantly higher in the semaglutide group compared with the DPP-4i group (mean change, +10.4 vs +0.6 in HOMA2-\u03b2 [P = .001] and +0.09 vs 0.0 in DI [P &amp;lt; .001]). Improvement in DI in the semaglutide group was correlated significantly to changes in body mass index (BMI), HbA1c, and fatty liver index reflecting liver steatosis. Multiple linear regression analysis revealed that dose of semaglutide (\u2265\u202f7\u2005mg\/day), reduction in fatty liver index, and metformin nonuse were independently associated with improvement of DI.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Switching to oral semaglutide ameliorated \u03b2-cell function compared with DPP-4is, presumably via tissue-to-tissue crosstalk between liver and \u03b2-cells.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgae213","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T12:40:47Z","timestamp":1714653647000},"page":"e583-e591","source":"Crossref","is-referenced-by-count":5,"title":["Improvement of \u03b2-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis"],"prefix":"10.1210","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0713-221X","authenticated-orcid":false,"given":"Hiroshi","family":"Nomoto","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Furusawa","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yokoyama","sequence":"additional","affiliation":[{"name":"Jiyugaoka Medical Clinic , Obihiro 080-0016 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimi","family":"Izumihara","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Oe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyohiko","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Division of Diabetes and Endocrinology, Department of Medicine, Hakodate Central General Hospital , Hakodate 040-8585 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aika","family":"Miya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiraku","family":"Kameda","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Yong","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Takeuchi","sequence":"additional","affiliation":[{"name":"Sapporo Diabetes and Thyroid Clinic , Sapporo 060-0807 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Kurihara","sequence":"additional","affiliation":[{"name":"Kurihara Clinic , Sapporo 004-0053 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinobu","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Atsumi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University , Sapporo 060-8638 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"2025021815503650000_dgae213-B1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.2337\/diab.44.11.1249","article-title":"U.K. Prospective diabetes study 16. Overview of 6 years\u2019 therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group","volume":"44","author":"Group","year":"1995","journal-title":"Diabetes"},{"key":"2025021815503650000_dgae213-B2","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.amjmed.2009.03.015","article-title":"Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use","volume":"122","author":"Kendall","year":"2009","journal-title":"Am J Med"},{"key":"2025021815503650000_dgae213-B3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2337\/diabetes.52.1.102","article-title":"Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes","volume":"52","author":"Butler","year":"2003","journal-title":"Diabetes"},{"key":"2025021815503650000_dgae213-B4","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1210\/jc.2016-1374","article-title":"Effects of obesity and diabetes on \u03b1- and \u03b2-cell mass in surgically resected human pancreas","volume":"101","author":"Inaishi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815503650000_dgae213-B5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2337\/dc19-0371","article-title":"Time course of normalization of functional \u03b2-cell capacity in the diabetes remission clinical trial after weight loss in type 2 diabetes","volume":"43","author":"Zhyzhneuskaya","year":"2020","journal-title":"Diabetes care"},{"key":"2025021815503650000_dgae213-B6","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1038\/s41467-023-40287-w","article-title":"Determinants of sustained stabilization of beta-cell function following short-term insulin therapy in type 2 diabetes","volume":"14","author":"Retnakaran","year":"2023","journal-title":"Nat Commun"},{"key":"2025021815503650000_dgae213-B7","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/dom.14969","article-title":"Beta-cell function in treatment-na\u00efve patients with type 2 diabetes mellitus: analyses of baseline data from 15 clinical trials","volume":"25","author":"Bl\u00fcher","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025021815503650000_dgae213-B8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1111\/dom.13613","article-title":"The effects of incretin-based therapies on \u03b2-cell function and insulin resistance in type 2 diabetes: a systematic review and network meta-analysis combining 360 trials","volume":"21","author":"Wu","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2025021815503650000_dgae213-B9","doi-asserted-by":"crossref","first-page":"e1369","DOI":"10.1136\/bmj.e1369","article-title":"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis","volume":"344","author":"Karagiannis","year":"2012","journal-title":"BMJ"},{"key":"2025021815503650000_dgae213-B10","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2025021815503650000_dgae213-B11","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.2337\/db05-1602","article-title":"Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes","volume":"55","author":"Mu","year":"2006","journal-title":"Diabetes"},{"key":"2025021815503650000_dgae213-B12","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.2040-1124.2010.00075.x","article-title":"GLP-1 receptor agonist attenuates endoplasmic reticulum stress-mediated \u03b2-cell damage in Akita mice","volume":"2","author":"Yamane","year":"2011","journal-title":"J Diabetes Investig"},{"key":"2025021815503650000_dgae213-B13","doi-asserted-by":"crossref","first-page":"e0236603","DOI":"10.1371\/journal.pone.0236603","article-title":"Comparisons between dipeptidyl peptidase-4 inhibitors and other classes of hypoglycemic drugs using two distinct biomarkers of pancreatic beta-cell function: a meta-analysis","volume":"15","author":"Takahashi","year":"2020","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"2025021815503650000_dgae213-B14","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/dom.13137","article-title":"Efficacy of glucagon-like peptide-1 receptor agonists compared to dipeptidyl peptidase-4 inhibitors for the management of type 2 diabetes: a meta-analysis of randomized clinical trials","volume":"20","author":"Tran","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025021815503650000_dgae213-B15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025021815503650000_dgae213-B16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2025021815503650000_dgae213-B17","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2025021815503650000_dgae213-B18","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S2213-8587(20)30074-7","article-title":"Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial","volume":"8","author":"Yabe","year":"2020","journal-title":"Lancet Diabet Endocrinol"},{"key":"2025021815503650000_dgae213-B19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"2025021815503650000_dgae213-B20","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1111\/dom.15393","article-title":"Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: a multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study)","volume":"26","author":"Furusawa","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"2025021815503650000_dgae213-B21","doi-asserted-by":"crossref","first-page":"e056885","DOI":"10.1136\/bmjopen-2021-056885","article-title":"Effects of switching from a dipeptidyl peptidase-4 inhibitor to oral semaglutide on glucose metabolism in patients with type 2 diabetes: protocol for a multicentre, prospective, randomised, open-label, parallel-group comparison study (the SWITCH-SEMA 2 study)","volume":"12","author":"Nomoto","year":"2022","journal-title":"BMJ Open"},{"key":"2025021815503650000_dgae213-B22","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.3390\/pharmaceutics15071838","article-title":"Favorable effect of pemafibrate on insulin resistance and \u03b2-cell function in subjects with type 2 diabetes and hypertriglyceridemia: a subanalysis of the PARM-T2D study","volume":"15","author":"Nomoto","year":"2023","journal-title":"Pharmaceutics"},{"key":"2025021815503650000_dgae213-B23","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.2337\/dc06-0070","article-title":"New insights on the simultaneous assessment of insulin sensitivity and beta-cell function with the HOMA2 method","volume":"29","author":"Caumo","year":"2006","journal-title":"Diabetes Care"},{"key":"2025021815503650000_dgae213-B24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.2337\/dc09-1463","article-title":"Estimates of insulin sensitivity using glucose and C-Peptide from the hyperglycemia and adverse pregnancy outcome glucose tolerance test","volume":"33","author":"Radaelli","year":"2010","journal-title":"Diabetes care"},{"key":"2025021815503650000_dgae213-B25","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1373\/clinchem.2016.257436","article-title":"Modification and validation of the triglyceride-to-HDL cholesterol ratio as a surrogate of insulin sensitivity in white juveniles and adults without diabetes Mellitus: the single point insulin sensitivity estimator (SPISE)","volume":"62","author":"Paulmichl","year":"2016","journal-title":"Clin Chem"},{"key":"2025021815503650000_dgae213-B26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver Index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"key":"2025021815503650000_dgae213-B27","doi-asserted-by":"crossref","unstructured":"Nomoto H, Furusawa S, Yokoyama H, et al \u00a0Date from: Improvement of \u03b2-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post-Hoc Analysis. Figshare. 2024. Repository date 10 February 2024. 10.6084\/m9.figshare.25199966.v1","DOI":"10.1210\/clinem\/dgae213"},{"key":"2025021815503650000_dgae213-B28","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1007\/BF00401145","article-title":"Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients","volume":"36","author":"Nauck","year":"1993","journal-title":"Diabetologia"},{"key":"2025021815503650000_dgae213-B29","doi-asserted-by":"crossref","first-page":"44865","DOI":"10.1038\/srep44865","article-title":"Effects of dipeptidyl peptidase-4 inhibitors on beta-cell function and insulin resistance in type 2 diabetes: meta-analysis of randomized controlled trials","volume":"7","author":"Lyu","year":"2017","journal-title":"Sci Rep"},{"key":"2025021815503650000_dgae213-B30","doi-asserted-by":"crossref","first-page":"672658","DOI":"10.1155\/2012\/672658","article-title":"Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis","volume":"2012","author":"Monami","year":"2012","journal-title":"Exp Diabetes Res"},{"key":"2025021815503650000_dgae213-B31","doi-asserted-by":"crossref","first-page":"769069","DOI":"10.3389\/fendo.2021.769069","article-title":"Efficacy and safety of GLP-1 receptor agonists in patients with type 2 diabetes Mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"12","author":"Zhu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025021815503650000_dgae213-B32","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.2337\/dc19-0749","article-title":"PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes","volume":"42","author":"Aroda","year":"2019","journal-title":"Diabetes Care"},{"key":"2025021815503650000_dgae213-B33","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.2337\/dc19-0883","article-title":"Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial","volume":"42","author":"Rodbard","year":"2019","journal-title":"Diabetes care"},{"key":"2025021815503650000_dgae213-B34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S2213-8587(20)30075-9","article-title":"Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2\/3a, randomised, controlled trial","volume":"8","author":"Yamada","year":"2020","journal-title":"Lancet Diabet Endocrinol"},{"key":"2025021815503650000_dgae213-B35","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jama.2019.2942","article-title":"Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: the PIONEER 3 randomized clinical trial","volume":"321","author":"Rosenstock","year":"2019","journal-title":"Jama"},{"key":"2025021815503650000_dgae213-B36","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.3390\/pharmaceutics15082163","article-title":"Effect of switching to once-weekly semaglutide on non-alcoholic fatty liver disease: the SWITCH-SEMA 1 subanalysis","volume":"15","author":"Nomoto","year":"2023","journal-title":"Pharmaceutics"},{"key":"2025021815503650000_dgae213-B37","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nrendo.2017.56","article-title":"Hepatokines: linking nonalcoholic fatty liver disease and insulin resistance","volume":"13","author":"Meex","year":"2017","journal-title":"Nat Rev Endocrinol"},{"key":"2025021815503650000_dgae213-B38","doi-asserted-by":"crossref","first-page":"892672","DOI":"10.3389\/fendo.2022.892672","article-title":"Contribution of liver and pancreatic islet crosstalk to \u03b2-cell function\/dysfunction in the presence of fatty liver","volume":"13","author":"L\u00f3pez-Bermudo","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025021815503650000_dgae213-B39","first-page":"3","article-title":"Systematic review and meta-analysis of circulating fetuin-A levels in nonalcoholic fatty liver disease","volume":"9","author":"Liu","year":"2021","journal-title":"J Clin Transl Hepatol"},{"key":"2025021815503650000_dgae213-B40","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1007\/s00125-021-05435-1","article-title":"The hepatokine fetuin-A disrupts functional maturation of pancreatic beta cells","volume":"64","author":"Gerst","year":"2021","journal-title":"Diabetologia"},{"key":"2025021815503650000_dgae213-B41","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1007\/s00125-017-4385-1","article-title":"Metabolic crosstalk between fatty pancreas and fatty liver: effects on local inflammation and insulin secretion","volume":"60","author":"Gerst","year":"2017","journal-title":"Diabetologia"},{"key":"2025021815503650000_dgae213-B42","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s42000-019-00127-3","article-title":"Selenium and selenoprotein P in nonalcoholic fatty liver disease","volume":"19","author":"Polyzos","year":"2020","journal-title":"Hormones"},{"key":"2025021815503650000_dgae213-B43","doi-asserted-by":"crossref","first-page":"16727","DOI":"10.1038\/s41598-018-35067-2","article-title":"Serum selenoprotein P, but not selenium, predicts future hyperglycemia in a general Japanese population","volume":"8","author":"Oo","year":"2018","journal-title":"Sci Rep"},{"key":"2025021815503650000_dgae213-B44","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cmet.2010.09.015","article-title":"A liver-derived secretory protein, selenoprotein P, causes insulin resistance","volume":"12","author":"Misu","year":"2010","journal-title":"Cell Metab"},{"key":"2025021815503650000_dgae213-B45","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s41467-017-01863-z","article-title":"Selenoprotein P-neutralizing antibodies improve insulin secretion and glucose sensitivity in type 2 diabetes mouse models","volume":"8","author":"Mita","year":"2017","journal-title":"Nat Commun"},{"key":"2025021815503650000_dgae213-B46","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2010.05.018","article-title":"Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride","volume":"53","author":"Li","year":"2010","journal-title":"J Hepatol"},{"key":"2025021815503650000_dgae213-B47","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1210\/jc.2018-02414","article-title":"Plasma fibroblast growth factor 21 is associated with severity of nonalcoholic steatohepatitis in patients with obesity and type 2 diabetes","volume":"104","author":"Barb","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2025021815503650000_dgae213-B48","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1111\/jcmm.14007","article-title":"Pancreatic fibroblast growth factor 21 protects against type 2 diabetes in mice by promoting insulin expression and secretion in a PI3\u2005K\/akt signaling-dependent manner","volume":"23","author":"Pan","year":"2019","journal-title":"J Cell Mol Med"},{"key":"2025021815503650000_dgae213-B49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3803\/EnM.2015.30.2.177","article-title":"Exendin-4 inhibits the expression of SEPP1 and fetuin-A via improvement of palmitic acid-induced endoplasmic Reticulum stress by AMPK","volume":"30","author":"Lee","year":"2015","journal-title":"Endocrinol Metabol"},{"key":"2025021815503650000_dgae213-B50","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.clinre.2020.01.007","article-title":"Effect of liraglutide therapy on serum fetuin A in patients with type 2 diabetes and non-alcoholic fatty liver disease","volume":"44","author":"Zhang","year":"2020","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"2025021815503650000_dgae213-B51","doi-asserted-by":"crossref","first-page":"106426","DOI":"10.1016\/j.phrs.2022.106426","article-title":"Glucagon-like peptide 1 and fibroblast growth factor-21 in non-alcoholic steatohepatitis: an experimental to clinical perspective","volume":"184","author":"Yadav","year":"2022","journal-title":"Pharmacol Res"},{"key":"2025021815503650000_dgae213-B52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jdiacomp.2016.09.001","article-title":"Metformin prevents glucotoxicity by alleviating oxidative and ER stress-induced CD36 expression in pancreatic beta cells","volume":"31","author":"Moon","year":"2017","journal-title":"J Diabetes Complicat"},{"key":"2025021815503650000_dgae213-B53","doi-asserted-by":"crossref","first-page":"10183","DOI":"10.1038\/s41598-018-28314-z","article-title":"Preventive treatment with liraglutide protects against development of glucose intolerance in a rat model of Wolfram syndrome","volume":"8","author":"Toots","year":"2018","journal-title":"Sci Rep"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgae213\/57382906\/dgae213.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e583\/57382906\/dgae213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/110\/3\/e583\/57382906\/dgae213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:11:34Z","timestamp":1739895094000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/110\/3\/e583\/7662554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,2]]},"references-count":53,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,5,2]]},"published-print":{"date-parts":[[2025,2,18]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgae213","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,3]]},"published":{"date-parts":[[2024,5,2]]}}}